Abstract
The combination of erlotinib and bevacizumab prolongs PFS in patients with EGFR-mutant NSCLC.
©2014 American Association for Cancer Research.
Publication types
-
Randomized Controlled Trial
MeSH terms
-
Angiogenesis Inhibitors / administration & dosage
-
Angiogenesis Inhibitors / adverse effects
-
Antibodies, Monoclonal, Humanized / administration & dosage
-
Antibodies, Monoclonal, Humanized / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Bevacizumab
-
Carcinoma, Non-Small-Cell Lung / drug therapy*
-
Carcinoma, Non-Small-Cell Lung / genetics
-
Disease-Free Survival
-
ErbB Receptors / genetics
-
Erlotinib Hydrochloride
-
Humans
-
Lung Neoplasms / drug therapy*
-
Lung Neoplasms / genetics
-
Mutation
-
Protein Kinase Inhibitors / administration & dosage
-
Protein Kinase Inhibitors / adverse effects
-
Quinazolines / administration & dosage
-
Quinazolines / adverse effects
-
Treatment Outcome
Substances
-
Angiogenesis Inhibitors
-
Antibodies, Monoclonal, Humanized
-
Protein Kinase Inhibitors
-
Quinazolines
-
Bevacizumab
-
Erlotinib Hydrochloride
-
EGFR protein, human
-
ErbB Receptors